<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066453</url>
  </required_header>
  <id_info>
    <org_study_id>2014_21</org_study_id>
    <secondary_id>2014-003882-10</secondary_id>
    <secondary_id>PHRC I 2013</secondary_id>
    <nct_id>NCT03066453</nct_id>
  </id_info>
  <brief_title>Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis</brief_title>
  <acronym>TOBRAMUC</acronym>
  <official_title>Evaluation of an Antibiotic Treatment With 14 Days of Intravenous Tobramycin Versus the Same Antibiotic Associated With 5 Days of Intravenous Tobramycin Followed by Tobramycin Aerosol for 9 Days in Cystic Fibrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the efficacy of antibiotic therapy with any
      antibiotic (IV) and IV (Nebcin®) tobramycin for 5 days followed by Solution for nebuliser
      inhalation (Tobi®) for 9 days and antibiotic cures using 14 days of tobramycin IV. In the
      case of positive results, the reduction of the duration of IV treatment of tobramycin from 14
      days to 5 days would limit the risk of toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2017</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced expiratory volume at one second (FEV1) by spirometry</measure>
    <time_frame>18 months of the cure</time_frame>
    <description>measure of dyspnea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume at one second (FEV1) by spirometry</measure>
    <time_frame>baseline and between day 16 or day 22</time_frame>
    <description>measure of dyspnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>baseline and between day 16 or day 22</time_frame>
    <description>measure of dyspnea, condition of patient, bronchial congestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with Bronchial congestion</measure>
    <time_frame>baseline and between day 16 or day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum sample culture</measure>
    <time_frame>baseline and between day 16 or day 22</time_frame>
    <description>a descriptive analysis of Pseudomonas aeruginosa, and the other bacteria in the bacterial flora of sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of the first exacerbation after the cure</measure>
    <time_frame>during 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pulmonary exacerbations and those leading to hospitalization</measure>
    <time_frame>during 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Standard cure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antibiotic IV (Nebcin) 14 days and 14 days of tobramycin IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short cure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>antibiotic IV (Nebcin)14 days but with only 5 days of tobramycin IV followed 9 days of inhaled tobramycin (Tobi Inhalant Product)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobi Inhalant Product</intervention_name>
    <description>inhaled tobramycin 300 mg twice per day</description>
    <arm_group_label>Standard cure</arm_group_label>
    <arm_group_label>Short cure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebcin</intervention_name>
    <description>10 to 12 mg/kg/day in 1 injection for adults and 10 to 12 mg/kg in 1 pediatric injection (combined with another IV antibiotic)</description>
    <arm_group_label>Standard cure</arm_group_label>
    <arm_group_label>Short cure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with cystic fibrosis confirmed by sweat or genetic test

          -  Patient with clinical signs of exacerbation (increased cough, sputum (abundance,
             purulence), fever, anorexia, weight loss and FEV1) or acute exacerbations (defined at
             the clinician's discretion )

          -  FEV1 ≥ 25%

          -  Pseudomonas aeruginosa chronic carriers (defined by at least two antipyocyanic
             precipitation arcs or at least 3 successive positive ECBCs over a period of 18 months)

          -  Patient who received at least 1 IV course of antibiotics in the year prior to
             inclusion.

        Exclusion Criteria:

          -  Severe exacerbation (requiring hospitalization due to severe amputation of FEV 1,
             oxygen deficiency, or severe impairment of general health).

          -  Patient colonized in Burkholderia cepacia

          -  Patient colonized by an atypical mycobacterium

          -  Patient with pulmonary transplant or transplant

          -  Hypersensitivity to tobramycin and other antibiotics of the aminoglycoside family

          -  Cirrhosis of Grades B and C according to the Child-Pugh Classification

          -  Myasthenia gravis

          -  Simultaneous administration of another aminoglycoside

          -  Renal failure

          -  Recent history of severe hemoptysis (within 2 months before inclusion)

          -  Antibiotic treatments prescribed in a systematic manner

          -  Patient participating simultaneously in another clinical study conducted on a drug for
             the duration of its participation in this research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Prévotat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Prévotat, MD</last_name>
    <phone>3.20.44.55.44</phone>
    <phone_ext>+33</phone_ext>
    <email>anne.prevotat@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CRCM pédiatrique - CHU d'Amiens Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Claire POULET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRCM mixte - CHU de Caen Hôpital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jacques BROUARD, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRCM mixte - CH de Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manuela SCALBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRCM mixte - CH de Lens</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sarah MITHA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRCM adulte - CHRU de Lille Hôpital Calmette</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Prévotat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRCM pédiatrique - CHRU de Lille Hôpital Jeanne de Flandres</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nathalie WIZLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRCM mixte - CHU de Rouen Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stéphane DOMINIQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystic fibrosis, tobramycin, antibiotic courses, FEV1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

